Wolfram Syndrome UK Conference 2023
I am thrilled to share my experience attending the Wolfram Syndrome UK conference 2023, which was held on September 30, 2023, to honor the Global Wolfram Syndrome Day on October 1st. It was a wonderful opportunity to present our therapeutic developments and ongoing and future clinical trial plans for Wolfram syndrome, and I was delighted […]
Therapeutic development – Progress Report
September 7, 2023 Dear Friends, Thank you so much for continually believing in and supporting me and our therapeutic development for Wolfram syndrome. I deeply appreciate it. Your encouragement has been such a driving force in our journey. Excitingly, we’re making significant strides in our therapeutic development for Wolfram syndrome. Ongoing clinical trial In collaboration […]
The Power of Hope: Lessons from Patients with Wolfram Syndrome
Recently, I saw two patients with Wolfram syndrome from Central America. Despite facing a debilitating disease, they had an inspiring positive attitude and gave me two wooden glasses, expressing their faith in me to find an effective treatment soon. This experience reminded me of the importance of hope and optimism in healthcare and how our […]
Highlights from the 8th International Wolfram Syndrome Symposium: Hope on the Horizon
The 8th International Wolfram Syndrome Symposium in London was a significant event for researchers and clinicians focused on this rare genetic disorder. The symposium fostered new collaborations and showcased the latest findings in Wolfram Syndrome research. We express our sincere appreciation to Stephanie Snow Gebel and Saad Naseer, MD, from the Snow Foundation, as well […]
United for a Cure: The International Wolfram Syndrome Symposium in London
The International Wolfram Syndrome Symposium begins tonight in London, bringing together 25 experts, including physicians, scientists, industry partners, and patient advocacy representatives, to explore cutting-edge treatments and strategies for this rare disease. Discussions will focus on enhancing patient outcomes, engaging the medical community, and advocating for public policy changes. Stay tuned, as I’ll be providing […]
A Ray of Hope: a girl of Israel
At our WFS1 clinic, we have the privilege of meeting extraordinary individuals who inspire and motivate us to push the boundaries of our Wolfram research. Today, I would like to share the story of a remarkable young girl from Israel who visited our clinic, leaving an indelible mark on our hearts and minds. Her courage, […]
First dose
We are excited to report that the Phase 2 Clinical Trial of AMX0035 for the Treatment of Wolfram Syndrome has commenced, with the first participant already dosed earlier this week. This marks our second clinical trial for Wolfram Syndrome, and we are incredibly grateful for the unwavering support from our patients, their families, and the […]
The Heartwarming Spirit of a Young Soccer Fan: A Glimpse into the Life of a 10-Year-Old with WFS1-Related Disorder
Last week, our clinical research unit welcomed a 10-year-old boy with WFS1-related disorder and his parents, who kindly donated their biological samples to support our research. The boy’s passion for soccer and life touched our hearts, and we want to share this heartwarming experience. The boy arrived wearing a Manchester City jersey, sparking conversation about […]
Upcoming clinical trials
There is an urgent need for new treatments and therapeutic approaches for Wolfram syndrome, including both oral and injectable medications. A promising strategy involves targeting upstream disease mechanisms to delay the progression of symptoms associated with Wolfram syndrome, such as optic nerve atrophy, neurodegeneration, and diabetes, through the use of oral medication. In pursuit of […]
Research Progress – October 4, 2022
Upcoming clinical trials We need new treatments and therapeutic modalities for Wolfram syndrome, including oral and injectable medications for optic nerve atrophy and neurological issues. I have been focusing my efforts on developing a new drug, AMX0035, to treat Wolfram syndrome in collaboration with Amylyx Pharmaceuticals in Cambridge, Massachusetts, USA. AMX0035 targets endoplasmic reticulum stress […]
Wolfram UK
I gave a talk for the Wolfram UK conference virtually last week. I updated the audience about our therapeutic development for Wolfram syndrome. The talk is now available via youtube. https://www.youtube.com/watch?v=pUyLPpwOM8Y Fumi URANO, MD, PhD
Gene Therapy Updates- Prime Editing
I have some exciting updates on our gene therapy development. The root cause of Wolfram syndrome is pathogenic changes in the WFS1 gene. Therefore, correcting these changes in the WFS1 gene is the best way to treat Wolfram syndrome. We initially used the original CRISPR-Cas9 gene editing technology and then used a newer technology, base […]